152 related articles for article (PubMed ID: 36974949)
1. Integrative exploration of the mutual gene signatures and immune microenvironment between benign prostate hyperplasia and castration-resistant prostate cancer.
Wu F; Ning H; Sun Y; Wu H; Lyu J
Aging Male; 2023 Dec; 26(1):2183947. PubMed ID: 36974949
[TBL] [Abstract][Full Text] [Related]
2. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
3. Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib.
Gong L; Tang Y; Jiang L; Tang W; Luo S
J Immunol Res; 2022; 2022():4065580. PubMed ID: 35910852
[TBL] [Abstract][Full Text] [Related]
4. Identification of castration-resistant prostate cancer-related hub genes using weighted gene co-expression network analysis.
Cheng Y; Li L; Qin Z; Li X; Qi F
J Cell Mol Med; 2020 Jul; 24(14):8006-8017. PubMed ID: 32485038
[TBL] [Abstract][Full Text] [Related]
5. Exploration of diagnostic biomarkers, microenvironment characteristics, and ursolic acid's therapeutic effect for benign prostate hyperplasia.
Chen Y; Xu H; Xu H; Liu C; Zhan M; Wang Z; Gu M; Chen Q; Xu B
Int J Biol Sci; 2023; 19(13):4242-4258. PubMed ID: 37705744
[TBL] [Abstract][Full Text] [Related]
6. De novo steroid biosynthesis in human prostate cell lines and biopsies.
Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
[TBL] [Abstract][Full Text] [Related]
7. Pirin: a potential novel therapeutic target for castration-resistant prostate cancer regulated by miR-455-5p.
Arai T; Kojima S; Yamada Y; Sugawara S; Kato M; Yamazaki K; Naya Y; Ichikawa T; Seki N
Mol Oncol; 2019 Feb; 13(2):322-337. PubMed ID: 30444038
[TBL] [Abstract][Full Text] [Related]
8. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression.
Latonen L; Afyounian E; Jylhä A; Nättinen J; Aapola U; Annala M; Kivinummi KK; Tammela TTL; Beuerman RW; Uusitalo H; Nykter M; Visakorpi T
Nat Commun; 2018 Mar; 9(1):1176. PubMed ID: 29563510
[TBL] [Abstract][Full Text] [Related]
9. A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data.
Huang J; Liu D; Li J; Xu J; Dong S; Zhang H
Ann Med; 2023; 55(2):2260387. PubMed ID: 37729607
[TBL] [Abstract][Full Text] [Related]
10. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract][Full Text] [Related]
11. Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.
Matsumoto T; Hatakeyama S; Yoneyama T; Tobisawa Y; Ishibashi Y; Yamamoto H; Yoneyama T; Hashimoto Y; Ito H; Nishimura SI; Ohyama C
Sci Rep; 2019 Nov; 9(1):16761. PubMed ID: 31727974
[TBL] [Abstract][Full Text] [Related]
12. Distinct Metabolic Signatures of Hormone-Sensitive and Castration-Resistant Prostate Cancer Revealed by a
Zheng H; Zhu Y; Shao X; Cai A; Dong B; Xue W; Gao H
J Proteome Res; 2020 Sep; 19(9):3741-3749. PubMed ID: 32702989
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets.
Rane JK; Scaravilli M; Ylipää A; Pellacani D; Mann VM; Simms MS; Nykter M; Collins AT; Visakorpi T; Maitland NJ
Eur Urol; 2015 Jan; 67(1):7-10. PubMed ID: 25234358
[TBL] [Abstract][Full Text] [Related]
14. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
[TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor in the prostate: A potential suppressor for benign prostatic hyperplasia and prostate cancer.
Chen R; Yu Y; Dong X
J Steroid Biochem Mol Biol; 2017 Feb; 166():91-96. PubMed ID: 27125450
[TBL] [Abstract][Full Text] [Related]
16. IMPORTANCE OF APOPTOSIS MARKERS (MDM2, BCL-2 AND Bax) IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER.
Saker Z; Tsintsadze O; Jiqia I; Managadze L; Chkhotua A
Georgian Med News; 2015 Dec; (249):7-14. PubMed ID: 26719543
[TBL] [Abstract][Full Text] [Related]
17. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
18. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
Kallio HML; Hieta R; Latonen L; Brofeldt A; Annala M; Kivinummi K; Tammela TL; Nykter M; Isaacs WB; Lilja HG; Bova GS; Visakorpi T
Br J Cancer; 2018 Aug; 119(3):347-356. PubMed ID: 29988112
[TBL] [Abstract][Full Text] [Related]
19. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
20.
Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
